Group 1 - Aktis Oncology Inc. plans to conduct an initial public offering (IPO) in the U.S. to raise up to $212 million [1] - The company intends to issue 11.8 million shares at a price range of $16-18 per share, leading to an estimated valuation of approximately $840 million [2] - Aktis specializes in developing α-particle radiotherapy for solid tumors and has raised about $346 million from top life sciences investors [2] Group 2 - As of September 30, the company reported revenue of $4.6 million and a net loss of $48.6 million for the nine months, compared to revenue of $554,000 and a net loss of $31.9 million in the same period the previous year [2] - Major shareholders before the IPO include MPM (26%), Vida Ventures (14%), EcoR1 (11%), and Blue Owl (7%) [3] - The IPO will be led by JPMorgan, Bank of America, Leerink Partners, and TD Securities, with plans to list on the NASDAQ under the ticker symbol AKTS [3]

Group 1 - Aktis Oncology Inc. plans to conduct an initial public offering (IPO) in the United States, aiming to raise up to $212 million [1] - The company intends to issue 11.8 million shares at a price range of $16 to $18 per share, potentially valuing the company at approximately $840 million [1] - Aktis specializes in developing alpha particle radiotherapy for solid tumors and was founded in 2021 [1] Group 2 - For the nine months ending September 30, the company reported revenues of $4.6 million and a net loss of $48.6 million, compared to revenues of $554,000 and a net loss of $31.9 million in the same period the previous year [1] - Aktis has raised approximately $346 million from top life sciences investors, including MPM, Vida, EcoR1 Capital, and Blue Owl Capital [2] - The IPO will be led by JPMorgan, Bank of America, Leerink Partners, and TD Securities, with plans to list on the NASDAQ under the ticker symbol AKTS [2]